Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Kimberly-Clark Corp.
KMBConsumer StaplesGenerated Aug 19, 2026, 11:15 PM UTC
KMB (Kimberly-Clark Corp.) analytical snapshot. Revenue declined +18.0% YoY to $16.45B. 5-year revenue CAGR -3.3%; 10y CAGR -1.1%. Net margin at 12.29% (expanding ▲). Market cap $36.54B at $109.88 per share. Trailing P/E 18.10, P/S 2.22, P/B 20.88. EV/Operating income ≈ 18.29 (EV $42.99B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -18 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Aug 4, 2026. 12 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 12, 2026.
- Latest quarterly report (10-Q) filed Aug 4, 2026.
- 12 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Kimberly-Clark Corp.; broad institutional reporting.
- Recent filers include INVESTORS TRUST CO /PA, INVESTORS TRUST CO /PA, INVESTORS TRUST CO /PA.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| INVESTORS TRUST CO /PA | 13F-HR | Feb 15, 2002 |
| INVESTORS TRUST CO /PA | 13F-HR | May 10, 2001 |
| INVESTORS TRUST CO /PA | 13F-HR | Oct 12, 2001 |
| INVESTORS TRUST CO /PA | 13F-HR | Jul 12, 2001 |
| Axiom Investment Management LLC | 13F-HR | Mar 16, 2021 |
| Date | Form | Description |
|---|---|---|
| Aug 4, 2026 | 8-K | 8-K |
| May 14, 2026 | 8-K | 2026 ANNUAL MEETING RESULTS |
| May 5, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Jan 29, 2026 | 8-K | FORM 8-K |
| Jan 27, 2026 | 8-K | 8-K |
| Jan 16, 2026 | 8-K | FORM 8-K |
| Dec 4, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Revenue grew -18.0% but receivables grew -5.8% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Receivables outpacing revenue: Accounts receivable grew -5.8% YoY vs revenue growth of -18.0%. The +12.2% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Free cash flow deteriorating: FCF declined +34.8% YoY (from $2.51B to $1.64B). With OCF at $2.78B and capex at $1.14B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
- Operating cash flow exceeds net income: OCF is 1.37x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: Revenue grew -18.0% but receivables grew -5.8% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
- 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Off-balance sheet arrangements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $20.06B | $16.45B | $-3.61B | -18.0% |
| Gross profit | $7.18B | $5.92B | $-1.26B | -17.5% |
| Operating income | $3.21B | $2.35B | $-859.0M | -26.8% |
| Net income | $2.54B | $2.02B | $-524.0M | -20.6% |
| Operating cash flow | $3.23B | $2.78B | $-457.0M | -14.1% |
| Capex | $721.0M | $1.14B | $417.0M | +57.8% |
| Total assets | $16.55B | $17.10B | $552.0M | +3.3% |
| Long-term debt | $6.70B | $7.40B | $698.0M | +10.4% |
| Cash & equivalents | $1.02B | $688.0M | $-333.0M | -32.6% |
| Stockholders equity | $840.0M | $1.50B | $662.0M | +78.8% |
| Inventory | $1.82B | $1.48B | $-347.0M | -19.0% |
| Accounts receivable | $2.01B | $1.89B | $-117.0M | -5.8% |
| R&D expense | $338.0M | $326.0M | $-12.0M | -3.6% |
| Interest expense | $270.0M | $256.0M | $-14.0M | -5.2% |
| Type | Concepts |
|---|---|
| Added | DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax, EquityMethodInvestmentsFairValueDisclosure, ProceedsFromDivestitureOfBusinesses |
| Removed | AccruedAdvertisingCurrent, AccruedSalariesCurrent, AdvertisingExpense, AllowanceForDoubtfulAccountsReceivableCurrent, AmortizationOfIntangibleAssets, AociLossCashFlowHedgeCumulativeGainLossAfterTax, AssetImpairmentCharges, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Impairment charge | medium | 5 | 6 | Ongoing |
| Restructuring | medium | 5 | 3 | Ongoing |
| Off-balance sheet arrangements | medium | 3 | 0 | NEW |
Fundamentals
Revenue declined +18.0% YoY to $16.45B. 5-year revenue CAGR -3.3%; 10y CAGR -1.1%. Net margin at 12.29% (expanding ▲).
- Revenue declined +18.0% YoY to $16.45B.
- 5-year revenue CAGR -3.3%; 10y CAGR -1.1%.
- Net margin at 12.29% (expanding ▲).
- Return on equity 134.55%, ROA 11.82%, ROIC 156.52%.
- Gross margin 36.01%, operating margin 14.29%.
- Free cash flow margin 9.97% ($1.64B).
- Net income down ▼ +20.6% YoY.
- Debt/equity 4.23, current ratio 0.91, net debt $6.45B.
- Asset turnover 0.89 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $20.06B | -1.8% | 35.80 | 16.00 | 12.69 | $2.51B | 302.98 |
| 2025 | $16.45B | -18.0% | 36.01 | 14.29 | 12.29 | $1.64B | 134.55 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2024 | $4.14B | -19.3% | — | 21.89% |
| Mar 31, 2025 | $4.05B | -21.3% | -2.2% | 13.99% |
| Jun 30, 2025 | $4.16B | -1.6% | +2.7% | 12.23% |
| Sep 30, 2025 | $4.15B | +0.1% | -0.3% | 10.75% |
| Mar 31, 2026 | $4.16B | +2.7% | +0.3% | 15.97% |
| Jun 30, 2026 | $4.19B | +0.6% | +0.6% | 8.24% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $36.54B at $109.88 per share. Trailing P/E 18.10, P/S 2.22, P/B 20.88. EV/Operating income ≈ 18.29 (EV $42.99B).
- Market cap $36.54B at $109.88 per share.
Price & Technicals
Price $109.88 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 49.28.
- Price $109.88 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 4.23 (high). Liquidity current ratio 0.91 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -18
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Kimberly-Clark Corp. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $109.88 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow KMB stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB● you | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |